Results for G 1/24
No claim interpretation summersaults for the EPO (T 2027/23) No claim interpretation summersaults for the EPO (T 2027/23) Reviewed by Dr Rose Hughes on Monday, September 01, 2025 Rating: 5
Divergence between the UPC and EPO on claim interpretation and description definitions (Agfa v Gucci, UPC_CFI_278/2023) Divergence between the UPC and EPO on claim interpretation and description definitions (Agfa v Gucci, UPC_CFI_278/2023) Reviewed by Dr Rose Hughes on Monday, August 11, 2025 Rating: 5
G 1/24 in the spotlight: Description definitions do not override clear claim language (T 1999/23) G 1/24 in the spotlight: Description definitions do not override clear claim language (T 1999/23) Reviewed by Dr Rose Hughes on Thursday, July 24, 2025 Rating: 5
Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy Reviewed by Dr Rose Hughes on Tuesday, May 27, 2025 Rating: 5
No back-pedaling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977) No back-pedaling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977) Reviewed by Dr Rose Hughes on Tuesday, April 22, 2025 Rating: 5
[GuestPost] G1/24: Tuning in! A take on the state of proceedings before oral proceedings [GuestPost] G1/24: Tuning in! A take on the state of proceedings before oral proceedings Reviewed by Dr Rose Hughes on Friday, March 28, 2025 Rating: 5
Powered by Blogger.